Skip to content
Peptilyze
CompoundsShopsCompareGuidesMethod
Metabolic research

Survodutide studies

136 journal papers mention Survodutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Survodutide is safe, effective or approved for any use.

Compare Survodutide prices, from €159.95 →

Papers
136
85 articles, 51 reviews
Earliest paper
2019
Most papers in 2026 (53)
Open access
68%
free to read somewhere
Reviews
38%
of all papers listed

What kind of studies

Of 95 papers in PubMed that mention Survodutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials10
  • Other clinical trials2
  • Meta-analyses and systematic reviews9
  • Other reviews50
  • Case reports0
  • Animal studies only0
  • Studies in humans59

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Registered clinical studies

Studies on ClinicalTrials.gov that mention Survodutide in their intervention details. A registration says a study is planned or running, not what it found.

Registered
36
Completed
25
Ongoing or planned
11
Phase 1
20
Phase 2
4
Phase 3
12
  1. ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

    NCT07850063Not yet recruitingPhase 3started 2026-11-02

  2. SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

    NCT07850050Not yet recruitingPhase 3started 2026-10-31

  3. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    NCT07754461RecruitingPhase 3started 2026-08-24

  4. A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

    NCT06077864CompletedPhase 3started 2023-11-20

  5. A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

    NCT07768813Active, not recruitingPhase 1started 2026-09-02

The five most recently updated studies. See all 36 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.

Papers per year

2019 to 2026, peak 53 papers in a year. The latest year may still be incomplete.

2019: 1 papers2020: 0 papers2021: 0 papers2022: 2 papers2023: 6 papers2024: 34 papers2025: 39 papers2026: 53 papers20192026

Where it is published

  1. Diabetes Obesity and Metabolism18 papers
  2. Diabetes15 papers
  3. Journal of the Endocrine Society4 papers
  4. Zeitschrift für Gastroenterologie3 papers
  5. Molecular Metabolism3 papers

The papers

ShowAllOpen accessReviews

Most citedName in the title

  1. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

    Arun Jayant Sanyal, Pierre Bédossa, Mandy Fraessdorf et al. · New England Journal of Medicine · 2024

    Randomized trial · Phase 2Open access · CC BY-NC-ND528 citationsRead the open copy →

  2. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

    Tina Zimmermann, Leo H. Thomas, Tamara Baader-Pagler et al. · Molecular Metabolism · 2022

    Study in humansOpen access · CC BY150 citationsRead the open copy →

  3. Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

    Matthias Blüher, Julio Rosenstock, Josef Hoefler et al. · Diabetologia · 2023

    Randomized trial · Phase 2Open access · CC BY138 citationsRead the open copy →

  4. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

    Arvid Jungnik, Jorge Arrubla, Leona Plum‐Mörschel et al. · Diabetes Obesity and Metabolism · 2022

    Clinical trial · Phase 1Open access · CC BY-NC63 citationsRead the open copy →

  5. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis

    Eric Lawitz, Mandy Fraessdorf, Guy W. Neff et al. · Journal of Hepatology · 2024

    Clinical trial · Phase 1Open access · CC BY57 citationsRead the open copy →

  6. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2)

    Sean Wharton, Carel Wynand le Roux, Mikhail Kosiborod et al. · Obesity · 2024

    Study in humansOpen access · CC BY-NC40 citationsRead the open copy →

  7. Survodutide for the Treatment of Obesity

    Mikhail Kosiborod, Elke Platz, Sean Wharton et al. · JACC Heart Failure · 2024

    Study in humansOpen access · CC BY37 citationsRead the open copy →

  8. Survodutide Once Weekly for the Treatment of Adults with Obesity

    Carel Wynand le Roux, Sean Wharton, E Startseva et al. · New England Journal of Medicine · 2026

    Randomized trial · Phase 3Open access · CC BY-SA25 citationsRead the open copy →

  9. Perspectives in weight control in diabetes – Survodutide

    Thomas Klein, Robert Augustin, Anita M. Hennige · Diabetes Research and Clinical Practice · 2023

    Study in humansOpen access · CC BY-NC25 citationsRead the open copy →

  10. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity

    Rie Yazawa, Masahiro Ishida, Yesilda Balavarca et al. · Diabetes Obesity and Metabolism · 2023

    Randomized trial · Phase 1Open access · CC BY-NC23 citationsRead the open copy →

  11. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

    Lee M. Kaplan, Elena Startseva, Carel Wynand le Roux et al. · Nature Medicine · 2026

    Randomized trial · Phase 3Open access · CC BY16 citationsRead the open copy →

  12. The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection

    Leo H. Thomas, Eric Martel, Wolfgang Rist et al. · Diabetes Obesity and Metabolism · 2024

    Study in humansOpen access · CC BY-NC-ND14 citationsRead the open copy →

  13. Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist

    Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas et al. · Diabetes Obesity and Metabolism · 2025

    Randomized trial · Phase 2Open access · CC BY-NC11 citationsRead the open copy →

  14. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1)

    Carel Wynand le Roux, Sean Wharton, Biykem Bozkurt et al. · Diabetes Obesity and Metabolism · 2025

    Randomized trial · Phase 3Open access · CC BY-NC8 citationsRead the open copy →

  15. Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial

    Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas et al. · Diabetes Obesity and Metabolism · 2024

    Open access · CC BY-NC8 citationsRead the open copy →

  16. Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials

    Haijun Wan, Nuo Xu, Lijuan Wang et al. · Diabetology & Metabolic Syndrome · 2024

    ReviewOpen access · CC BY-NC-ND8 citationsRead the open copy →

  17. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

    Sean Wharton, Carel Wynand le Roux, Elena Startseva et al. · New England Journal of Medicine · 2026

    Open access · CC BY-SA6 citationsRead the open copy →

  18. Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide

    Robert Augustin, Anouk Oldenburger, Tamara Baader-Pagler et al. · Molecular Metabolism · 2025

    Study in humansOpen access · CC BY-NC-ND6 citationsRead the open copy →

  19. Baseline characteristics in the SYNCHRONIZE ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ GLP ‐1 receptor dual agonist, for obesity in people with type 2 diabetes

    Sean Wharton, Carel Wynand le Roux, Biykem Bozkurt et al. · Diabetes Obesity and Metabolism · 2025

    Randomized trial · Phase 3Open access · CC BY-NC5 citationsRead the open copy →

  20. Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis

    Deep Dutta, Abul B. M. Kamrul-Hasan, Ameya S Joshi et al. · Indian Journal of Endocrinology and Metabolism · 2025

    ReviewOpen access · CC BY-NC-SA4 citationsRead the open copy →

  21. Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes

    Nasser E. Mikhail · Endocrinology and Disorders · 2024

    Open access · CC BY4 citationsRead the open copy →

  22. Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials

    Abdelaziz A. Awad, Alaa Abdrabou Abouelmagd, Fatma Mohammed et al. · Baylor University Medical Center Proceedings · 2025

    ReviewOpen access3 citationsRead the open copy →

  23. Nephroprotective Effects of the Dual GCGR / GLP ‐ 1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

    Alexander Hamilton, Louise Thisted, Maria Ougaard et al. · Diabetes Obesity and Metabolism · 2026

    Open access · CC BY-NC-ND2 citationsRead the open copy →

  24. Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation

    Tina Zimmermann, Katherin Bleymehl, Peter Haebel et al. · Molecular Metabolism · 2026

    Study in humansOpen access · CC BY2 citationsRead the open copy →

  25. Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE ‐1 survodutide study

    Baodong Wang, Jiayuan Huang, Zhiyun Chen · Diabetes Obesity and Metabolism · 2025

    Open access2 citationsRead the open copy →

  26. Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR / GLP ‐ 1R agonist survodutide in mice

    Fen Long, Tenagne D. Challa, Vissarion Efthymiou et al. · Diabetes Obesity and Metabolism · 2025

    Open access · CC BY2 citationsRead the open copy →

  27. Weight reduction–dependent/–independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH

    Mazen Noureddin, Arun Jayant Sanyal, Pierre Bédossa et al. · Hepatology · 2026

    Open access · CC BY-NC-ND1 citationsRead the open copy →

  28. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial

    Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima et al. · Diabetes Obesity and Metabolism · 2026

    Study in humansOpen access · CC BY-NC1 citationsRead the open copy →

  29. Survodutide for the Treatment of Obesity

    Elke Platz, Lee M. Kaplan, Carel Wynand le Roux et al. · JACC Heart Failure · 2025

    Open access · CC BY1 citationsRead the open copy →

  30. Survodutide, a new horizon in the treatment of obesity and Type 2 diabetes mellitus: A narrative review

    Abdelmoneim B. Yousif, Mohamed Fawzi Mudarres, Musaab Fahmi Yousef et al. · Yemen Journal of Medicine · 2024

    ReviewOpen access · CC BY-NC-SA1 citationsRead the open copy →

LatestName in title or abstract

  1. Charcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides

    Mary Sanville, Richard Dambra, Emily Werth et al. · The AAPS Journal · 2026

    Study in humansOpen access · CC BYRead the open copy →

  2. EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW

    Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026

    ReviewOpen accessRead the open copy →

  3. From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism

    Héctor Iván Saldívar-Cerón, Daniela Maldonado-Trejo, Quetzal Chavez-Castañeda et al. · International Journal of Molecular Sciences · 2026

    Open access · CC BYRead the open copy →

  4. From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease

    Christiano Argano, Dalila Maggio, Chiara Pollicino et al. · Frontiers in Pharmacology · 2026

    ReviewOpen access · CC BYRead the open copy →

  5. Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?

    Jiaxin He · Diabetes Obesity and Metabolism · 2026

    Open accessRead the open copy →

  6. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction–Associated Steatohepatitis—A Narrative Review with a Translational Focus

    Jamy D. Ard, Jaime P. Almandoz · Obesity Reviews · 2026

    ReviewOpen accessRead the open copy →

  7. Nephroprotective Effects of the Dual GCGR / GLP ‐ 1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

    Alexander Hamilton, Louise Thisted, Maria Ougaard et al. · Diabetes Obesity and Metabolism · 2026

    Open access · CC BY-NC-ND2 citationsRead the open copy →

  8. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

    Sean Wharton, Carel Wynand le Roux, Elena Startseva et al. · New England Journal of Medicine · 2026

    Open access · CC BY-SA6 citationsRead the open copy →

  9. The metabolic paradigm shift in gastroenterology and hepatology: Clinical applications of incretin-based co-agonists

    Abdulrahman Ismaiel, Dan Lucian Dumitrascu · Best Practice & Research Clinical Gastroenterology · 2026

    Open access · CC BY-NCRead the open copy →

  10. Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

    Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  11. Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

    Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · Diabetes Obesity and Metabolism · 2026

    ReviewOpen accessRead the open copy →

  12. ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES

    Aleksandra Wielogórska, Olga Stasiak, Filip Kowalik et al. · International Journal of Innovative Technologies in Social Science · 2026

    Open access · CC BYRead the open copy →

  13. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review

    Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  14. Pharmacological management of obesity: Current landscape and emerging therapies

    Shubham Atal, Chirag Agrawal, Rahul Gupta et al. · Indian Journal of Pharmacology · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  15. Glucagon is terug: survodutide opent nieuw hoofdstuk in obesitas en MASLD

    Marcel H.A. Muskiet · Nederlands Tijdschrift voor Diabetologie · 2026

    Open access · CC BY-NC-NDRead the open copy →

  16. Essai de phase 3 du survodutide administré une fois par semaine pour le traitement de l’obésité chez l’adulte : SYNCHRONIZE™-1

    Emmanuel Disse, C. Crepin, O. Halli · Annales d Endocrinologie · 2026

    Open accessRead the open copy →

  17. Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum

    Zishu Zhao, Xiaoyang Hu · Biomedicines · 2026

    ReviewOpen access · CC BYRead the open copy →

  18. Synchronizing obesity management with survodutide

    Amedeo Lonardo, Ralf Weiskirchen · Exploration of Drug Science · 2026

    Open access · CC BYRead the open copy →

  19. Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)

    Linong Ji, Liming Chen, Zhifeng Cheng et al. · Diabetes Therapy · 2026

    Open access · CC BY-NCRead the open copy →

  20. Anti-Obesity Medications in Longevity and Aesthetic Medicine

    Julia Bijoch · Journal of Clinical Medicine · 2026

    ReviewOpen access · CC BYRead the open copy →

  21. Weight reduction–dependent/–independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH

    Mazen Noureddin, Arun Jayant Sanyal, Pierre Bédossa et al. · Hepatology · 2026

    Open access · CC BY-NC-ND1 citationsRead the open copy →

  22. Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon‐Like Peptide‐1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus

    Pamela R. Kushner, Erin D. Michos · Journal of the American Heart Association · 2026

    ReviewOpen access · CC BY1 citationsRead the open copy →

  23. Incretin analogues as cardiovascular agents: a state-of-the-art review

    Diego Araiza Garaygordobil, Jorge E. Rico-Fontalvo, Betsabe Hernández-Balbuena et al. · Frontiers in Endocrinology · 2026

    ReviewOpen access · CC BY1 citationsRead the open copy →

  24. Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis

    Rogelio Santos Solís, Armando Baeza-Zapata, Juan Pablo Negrete‐Najar · Cureus · 2026

    ReviewOpen access · CC BYRead the open copy →

  25. Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

    Elif Ilhan Ekinci, Sandra González Maldonado, Anna Unseld et al. · Diabetes Obesity and Metabolism · 2026

    Randomized trial · Phase 2Open access · CC BY-NCRead the open copy →

  26. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

    Lee M. Kaplan, Elena Startseva, Carel Wynand le Roux et al. · Nature Medicine · 2026

    Randomized trial · Phase 3Open access · CC BY16 citationsRead the open copy →

  27. Survodutide Once Weekly for the Treatment of Adults with Obesity

    Carel Wynand le Roux, Sean Wharton, E Startseva et al. · New England Journal of Medicine · 2026

    Randomized trial · Phase 3Open access · CC BY-SA25 citationsRead the open copy →

  28. How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

    Jaime P. Almandoz, Alexander Dimitri Miras, Jochen Seufert et al. · Therapeutic Advances in Gastroenterology · 2026

    ReviewOpen access · CC BYRead the open copy →

  29. Beyond Semaglutide: The Rise of Multi-Agonist Incretin Therapy in Obesity and Metabolic Disease – A Comprehensive Pharmacological Review

    Dr. R. L. Manisha, Balasukula Rachana, Muvvala Sudhakar · International Journal of Innovative Science and Research Technology (IJISRT) · 2026

    Open access · CC BY-NCRead the open copy →

Each list shows up to 40 papers.See all 136 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.